Gendicine

AXP000141.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, E1 region replaced by a p53 expression cassette)
Targets
TP53
Originator
Shenzhen SiBiono GeneTech
Sponsor
Shenzhen SiBiono GeneTech

Names

NameTypeSource
Gendicinepreferred name, brandcurator, ncit
Genkaxinbrandncit
rAd-p53 ambiguouscodencit
Recombinant Adenovirus Encoding p53 ambiguoussynonymncit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
E1 region replaced by a human wild-type p53 expression cassette (replication-defective)
Transgenes
TP53
Route
intratumoral, intra arterial
Source
evidence

Cross-references

NCI Thesaurus
C85485

Approvals

AgencyRegionDateStatusBrandIndicationSource
NMPACN2003-10-16approvedGendicineHead and neck squamous cell carcinoma, with radiotherapysource

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02429037P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck CancerUnknownPhase 22015-052018-1260Advanced Head and Neck Cancer
NCT02418988Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular CarcinomaUnknownPhase 22014-072017-05120Advanced Adult Hepatocellular Carcinoma
NCT01574729Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell CarcinomaUnknownPhase 22012-082015-08120Non-small Cell Lung Cancer
NCT00902122rAd-p53 Gene Therapy for Advanced Malignant Thyroid TumorsUnknownPhase 42009-052012-08600Advanced Malignant Thyroid Tumors
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT00902083rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant TumorsUnknownPhase 42009-062012-07600Advanced Oral and Maxillofacial Malignant Tumorsname in title: rAd-p53

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41573652TACE combined with sorafenib induces complete remission in an elderly patient with hepatocellular carcinoma, hepatic venous tumor thrombus, and diffuse lung metastasis: a case study and literature review.Frontiers in oncology2025name in abstract: Gendicine
PMID 24457472Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma.American journal of clinical oncology2014name in abstract: Gendicine
PMID 24842203[The preliminary study of recombinant adenovirus p53 combined with transarterial embolization with particles for advanced hepatocellular carcinoma].Zhonghua yi xue za zhi2014name in abstract: Gendicine
PMID 19882171Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma.Journal of cancer research and clinical oncology2010name in abstract: Gendicine
PMID 19318914A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization.Anti-cancer drugs2009name in abstract: Gendicine
PMID 19375021Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia.Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons2009name in abstract: Gendicine
PMID 15879012p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma.Gut2005name in title: Gendicine
PMID 15968745Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization.World journal of gastroenterology2005name in abstract: Gendicine
PMID 16188130[Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].Zhonghua zhong liu za zhi [Chinese journal of oncology]2005name in abstract: Gendicine
Unconfirmed matches (4)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 32851960Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.Current gene therapy2020name in title: rAd-p53
PMID 26146864A patient with a large intrathoracic malignant schwannoma who showed a complete clinical response to rAd-p53-combined with radiotherapy.Anti-cancer drugs2015name in title: rAd-p53
PMID 24479409Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial.BMC medicine2014name in title: rAd-p53
PMID 12082455A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.Cancer gene therapy2002name in title: rAd-p53

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42248643Non-replicating adenoviral vectors for cancer gene therapy.Advances in cancer research2026name in abstract: Gendicine
PMID 40227707Gene and Cell Therapy for Sarcomas: A Review.Cancers2025name in abstract: Gendicine
PMID 38523676Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology.Genes & diseases2024name in title: Gendicine
PMID 36154608Gene Therapy Cargoes Based on Viral Vector Delivery.Current gene therapy2023name in abstract: Gendicine
PMID 36992407Viral Vectors in Gene Therapy: Where Do We Stand in 2023?Viruses2023name in abstract: Gendicine
PMID 37065938Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health.Translational medicine communications2023name in abstract: Gendicine
PMID 37323391Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases.ACS omega2023name in abstract: Gendicine
PMID 38132123The Role of p53 in Nanoparticle-Based Therapy for Cancer.Cells2023name in abstract: Gendicine
PMID 35756634Role of Adenoviruses in Cancer Therapy.Frontiers in oncology2022name in abstract: Gendicine
PMID 34785635Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers.International journal of oral science2021name in abstract: Gendicine
PMID 32528163An overview of development in gene therapeutics in China.Gene therapy2020name in abstract: Gendicine
PMID 32951572Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.Current gene therapy2020name in abstract: Gendicine
PMID 33013864Externally-Controlled Systems for Immunotherapy: From Bench to Bedside.Frontiers in immunology2020name in abstract: Gendicine
PMID 31933185Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.Pharmaceutical medicine2019name in abstract: Gendicine
PMID 29179583Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy.Human gene therapy2018name in abstract: Gendicine
PMID 29281902Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy.Human gene therapy2018name in title: Gendicine
PMID 29334764Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside.Human gene therapy2018name in abstract: Gendicine
PMID 29338444The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.Human gene therapy2018name in title: Gendicine
PMID 29445265New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Biologics : targets & therapy2018name in abstract: Gendicine
PMID 30305211Noninvasive and Local Delivery of Adenoviral-Mediated Herpes Simplex Virus Thymidine Kinase to Treat Glioma Through Focused Ultrasound-Induced Blood-Brain Barrier Opening in Rats.Journal of biomedical nanotechnology2018name in abstract: Gendicine
PMID 27548881The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery.Expert opinion on drug delivery2017name in abstract: Gendicine
PMID 29018892Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.Archives of toxicology2017name in abstract: Gendicine
PMID 27843742Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysis.SpringerPlus2016name in abstract: Gendicine
PMID 27976709Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion.Scientific reports2016name in abstract: Gendicine
PMID 25496374Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors.Expert opinion on biological therapy2015name in title: Gendicine
PMID 26259388Strategies used in the clinical trials of gene therapy for cancer.Journal of experimental therapeutics & oncology2015name in abstract: Gendicine
PMID 26402250Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.Expert review of anticancer therapy2015name in abstract: Gendicine
PMID 25364261Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.OncoTargets and therapy2014name in abstract: Gendicine
PMID 23840897Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.PloS one2013name in abstract: Gendicine
PMID 24107178Advances in adenovirus-mediated p53 cancer gene therapy.Expert opinion on biological therapy2013name in abstract: Gendicine
PMID 24385699Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu2013name in title: Gendicine
PMID 24385704Clinical antiangiogenic effect of recombinant adenovirus-p53 combined with hyperthermia for advanced cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu2013name in abstract: Gendicine
PMID 22970051Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells.Oncology letters2012name in abstract: Gendicine
PMID 23021247Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.Advances in cancer research2012name in abstract: Gendicine
PMID 21942125Updates on current advances in gene therapy.The West Indian medical journal2011name in abstract: Gendicine
PMID 20679889p53 gene therapy for pulmonary metastasis tumor from hepatocellular carcinoma.Anti-cancer drugs2010name in abstract: Gendicine
PMID 21042759Synergistic gastric cancer inhibition by chemogenetherapy with recombinant human adenovirus p53 and epirubicin: an in vitro and in vivo study.Oncology reports2010name in abstract: Gendicine
PMID 19508919Targeted genetic and viral therapy for advanced head and neck cancers.Drug discovery today2009name in abstract: Gendicine
PMID 19806503An update on gene therapy in China.Current opinion in molecular therapeutics2009name in abstract: Gendicine
PMID 18465676The application of gene therapy in China.IDrugs : the investigational drugs journal2008name in abstract: Gendicine
PMID 19186869[Biologic analysis of recombinant human adenovirus-p53 injection in patients with oral leukoplakia ].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology2008name in abstract: Gendicine
PMID 20021420Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications.Current molecular pharmacology2008name in abstract: Gendicine
PMID 17047133p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma.Gut2006name in title: Gendicine
PMID 17124301Chinese gene therapy. Gendicine's efficacy: hard to translate.Science (New York, N.Y.)2006name in title: Gendicine
PMID 21144296[Effect of recombinant adenovirus-p53 on growth and chemosensitivity of human lung adenocarcinoma cell lines].Zhongguo fei ai za zhi = Chinese journal of lung cancer2006name in abstract: Gendicine
PMID 16146351DNA-based therapeutics and DNA delivery systems: a comprehensive review.The AAPS journal2005name in abstract: Gendicine
PMID 16149899Gendicine: the first commercial gene therapy product.Human gene therapy2005name in title: Gendicine
PMID 16149900Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.Human gene therapy2005name in title: Gendicine
Unconfirmed matches (10)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 32013587Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-p53 Combined with Chemotherapy Treatment.Human gene therapy2020name in title: rAd-p53
PMID 33060772Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models.Scientific reports2020name in title: rAd-p53
PMID 29328445The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma.Molecular medicine reports2018name in title: rAd-p53
PMID 30405797Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer.Oncology letters2018name in title: rAd-p53
PMID 28621316Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.Cancer gene therapy2017name in title: rAd-p53
PMID 27446369Recurrent myoepithelial carcinoma of the submandibular gland treated by rAd-p53 combined with radiotherapy: A case report.Oncology letters2016name in title: rAd-p53
PMID 22441128Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo.Gene2012name in title: rAd-p53
PMID 22090785rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy.World journal of gastroenterology2011name in title: rAd-p53
PMID 20678439[Experimental studies of rAd-p53 injection by interventional approach for the treatment of rabbit VX2 liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2010name in title: rAd-p53
PMID 17129471[The combination of recombinant rAd-p53 and adriamycin for management of primary drug resistance in chemotherapy of lung squamous cell cancer].Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases2006name in title: rAd-p53

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R21CA241015Re-engineered Mitochondrially Targeted p53 Gene Therapy in Liver CancerUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHLIM, CAROL S.2021–2022name in abstract: Gendicine

Notes

First gene therapy approved anywhere: SFDA (now NMPA) licence 16 October 2003 for head and neck squamous cell carcinoma, launched April 2004. Replication-defective Ad5 with the E1 region replaced by a wild-type human p53 cassette; promoter not verified. Distinct from contusugene ladenovec (AXP000142) and SCH-58500 (AXP000152), which are separate Ad-p53 constructs.

How to cite

Gendicine (AXP000141.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000141.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.